Multicentre, binational, prospective, randomized, open, blinded end-point, randomized, register-based, clinical trial.
Patients undergoing first isolated nonemergent CABG were randomized 1:1 to no-touch or conventional open skeletonized saphenous vein graft harvesting technique. 902 patients were included from March 2018 until May 2020 in all eight Swedish centres and Aarhus University Hospital (265 patients).
The primary end point is the proportion of patients with graft failure defined as SVGs occluded or stenosed >50% on coronary computed tomography angiography at 2 years after CABG, earlier clinically driven coronary angiography demonstrating an occluded or stenosed >50% vein graft, or death within 2 years.
The secondary end points include wound healing in the vein graft sites and the composite outcome of major adverse cardiac events during the first 2 years based on registry data.
The Swedish Research Council (Vetenskapsrådet) and the Swedish Heart and Lung Foundation (Hjärt-Lungfonden).